St. Jude Children’s Research Hospital press release
Adolescents with HIV in Botswana, South Africa, Thailand, Uganda and the United States who received the injectable intramuscular antiviral medications cabotegravir and rilpivirine for nearly a year after being switched from daily oral HIV medications, which they had been on most of their life, experienced no major safety concerns, had continued viral suppression and greatly preferred the new treatment method.
The findings, published in two companion papers in The Lancet HIV, are the latest results from the National Institutes of Health-funded International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Network clinical trial, which is co-led by investigators at St. Jude Children’s Research Hospital in the United States and the Centre for Infectious Disease Research in Zambia.
Read the full press release here.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.